Epicrispr raises $90 million to push epigenetic editing drug EPI-321 for rare muscle disorder FSHD

Epicrispr Biotechnologies announced a $90 million Series C financing to accelerate development of its epigenetic editing therapy EPI-321 for facioscapulohumeral muscular dystrophy (FSHD), a rare genetic muscle disorder.

The drug uses CRISPR-based epigenetic editing to silence the disease-causing gene without altering the DNA sequence, a strategy touted as potentially safer than conventional gene editing.

The company also reported that enrollment in its early-stage clinical study has been completed, marking a key milestone for the program.

CEO Amber Salzman described the funding as a pivotal step toward bringing the next generation of programmable epigenetic medicines to patients.